ArticleJournal of clinical microbiology2004
Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.The Journal of infectious diseases · 2010Pooled it
- Viral hepatitis and pregnancy.Nature reviews. Gastroenterology & hepatology · 2021Review
- Comparison of Abbott and Da-an real-time PCR for quantitating serum HBV DNA.World journal of gastroenterology · 2014Article
- Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.Journal of viral hepatitis · 2014Article
- Detection of HBV DNA in cerumen and sera of hbsag negative patients with chronic hepatitis B infection.Iranian Red Crescent medical journal · 2012Article
- LNA real-time PCR probe quantification of hepatitis B virus DNA.Experimental and therapeutic medicine · 2012Article
- Evaluation of Chronic Hepatitis B Infection in Patients with Seronegative HbsAg.Iranian journal of public health · 2012Article
- Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.The Journal of molecular diagnostics : JMD · 2011Review
- Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance.World journal of gastroenterology · 2010Article
- Nuclease-resistant double-stranded DNA controls or standards for hepatitis B virus nucleic acid amplification assays.Virology journal · 2009Article
- Molecular testing in the diagnosis and management of chronic hepatitis B.Clinical microbiology reviews · 2007Review
- Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.Journal of clinical microbiology · 2006Article
- Automated extraction of viral-pathogen RNA and DNA for high-throughput quantitative real-time PCR.Journal of clinical microbiology · 2005Article
- Detection and monitoring of virus infections by real-time PCR.Molecular aspects of medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent clinical studies suggest that hepatitis B virus (HBV) load and genotype may be independent predictors of responses to antiviral therapies. However, it is difficult for clinicians to accurately determine viral loads in patient samples because results--both the values and the units of measure--can vary greatly among different tests. Accordingly, the World Health Organization (WHO) has produced the first international standard for HBV DNA for nucleic acid amplification technology (NAT) assays. In the present study, we describe the performance of the target-capture PCR HBV DNA quantitative assay for the quantitation of HBV DNA in clinical samples and reference panels. The range of quantitation was between 50 and 10(10) IU/ml. The sensitivity and accuracy of the target-capture PCR assay were demonstrated by using the HBV panel from Quality Control for Medical Diagnostics (QCMD) and the WHO HBV DNA standard. The target-capture PCR assay quantitated the six genotype A members of the QCMD panel and dilutions of the WHO HBV DNA standard within an accuracy of 74 to 142%. Compared to current serological methods, the assay offers window period reductions of 19 days prior to HBV surface antigen and 26 days prior to HBV e antigen detection. The target-capture PCR assay was also compared with four commercially available NAT assays, and the various units of measure were standardized with respect to the international units of the WHO HBV DNA standard. The target-capture PCR assay is a sensitive, accurate, high-throughput, rapid, and reproducible assay for the determination of HBV loads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.